LANZOL 30

LANZOL 30

LANZOL 30

Anti-Ulcer/Acid/Flatulence

 Lansoprazole belongs to a class of antisecretory
  compounds,that do not exhibit anticholinergic or
  histamin H2-receptor antagonist properties ,but that 
 suppress gastric acid secretion that acts by specific 
 inhibition of the H+/K+-ATPase enzyme system.
- Lansoprazole may be useful in patients failing on a 
 histamine H2-receptor antagonist (Cimetidine,
  Ranitidine, Famotidine or Nizatidine).
- Absorption of lansoprazole begins only after the pellets 
 leave the stomach. Absorption is rapid, with peak plasma
  concentrations achieved about 1.5 hours after a dose by 
 mouth; bioavailability is reported to be 80% or more even 
 with the first dose.
- lansoprazole is extensively metabolized in the liver and
 excreted primarily in faces via  bile,only about 15 to
 30% of a dose is excreted in urine the plasma elimination 
 half-life is around 1.4 to 2 hours but the duration of action
  is much longer . 

Indecation

 LANZOL® is indicated in the treatment of: 
- Gastro-oesophageal reflux disease; 
- Peptic ulcer disease (duodenal and gastric ulcers;) 
- Zollinger-Ellison syndrome; 
- Erosive Esophagitis; 
- Acid related dyspepsia. 

Dosage & Administration

- It is normally taken before food in the morning.  
- Gastro-oesophageal reflux disease: 30 mg daily by  
 mouth for 4–8 weeks; thereafter maintenance therapy can 
 be continued with 15 or 30 mg daily according to
  response. 
- Peptic ulcer disease: 30 mg once daily. Treatment is 
 continued for 4 weeks for duodenal ulcer and 8 weeks 
for gastric ulcer.15 mg daily has also been recommended 
 as maintenance therapy for the prevention of relapse of 
 duodenal ulcer. 
- Zollinger-Ellison syndrome: the initial dose is 60 mg 
 daily, adjusted as required. Doses of up to 90 mg twice 
 daily have been used. 
- Erosive Esophagitis: 30 mg once daily for up to 8 
  weeks. 

- In triple therapy regimens for elimination of
 Helicobacter pylori in peptic ulcer disease: effective 
 regimens include LANZOL® 30 mg twice daily combined 
 with Clarithromycin 250 mg twice daily and either
 Amoxicillin 1g  twice  daily  or Metronidazole 400 mg
 twice daily; LANZOL®, Amoxicillin, and Metronidazole 
 has also been used. 
- In patients with NSAID-associated ulceration: a dose of 
 15 or 30 mg daily for 4–8 weeks is recommended.  
- For the relief of acid-related dyspepsia: LANZOL® may 
 be given in doses of 15 or 30 mg daily for 2–4 weeks.
- Or as directed by the physician. 

- Each capsule of LANZOL® 30 contains:
     Lansoprazole (as enteric coated pellets)    30 mg
- Each capsule of LANZOL® 15 contains: 
     Lansoprazole (as enteric coated pellets)    15 mg

- Hypersensitivity to lansoprazole. 

- Antacids and sucralfate may reduce the bioavailability of
   LANZOL® , and should not be taken within 1 hour of a
  dose of LANZOL® . 
- Lansoprazole is thought to be a weak inducer of hepatic 
 cytochrome P450, and may affect the pharmacokinetics of 
 the drugs which are metabolized by this system. 
- LANZOL® may interferes with the absorption of drugs
  where gastric pH is important determinant of bioavailability, 
 (e.g. Ketoconazole, Iron salts, Ampicillin esters, and 
 Digoxin). 

- LANZOL® should not be administered during pregnancy
  and lactation unless strictly indicated according to the 
 physician recommendations.


- LANZOL® has been well tolerated in both short-term and
  long-term treatment. 
- The most commonly reported possibly or probably 
 treatment-related a dverse event during maintenance therapy 
 was diarrhea. 

- Symptomatic response to therapy with LANZOL® does 
 not preclude the presence of gastric malignancy. 
- Dosage should be reduced in hepatic impairment. 

- LANZOL® Plastic jar of 14 capsules with a desiccant .
- LANZOL® Pack  of 10  strips each strips containe  
10 capsules.

Store in a dry place below 30 °C, protected from light and
  humidity.